Company Overview and News

24
Attempting To Clarify Transocean's Fleet Situation

2018-06-18 seekingalpha
Transocean will "retire in an environmentally responsible way" four floaters from its fleet and take an accompanying $520 million charge in the second quarter.
SMBMF RDS.B S51 RDS.A RYDBF RDSB RDSA RYDAF RIG SMBMY

1
Sembcorp Marine scores first polar expedition cruise ship design contract

2018-06-12 theedgemarkets
SINGAPORE (June 12): Sembcorp Marine announced that its fully-owned subsidiary, LMG Marin, has secured its first polar expedition cruise ship design contract, sighed with Croatia’s Brodosplit Shipyard.
SMBMF S51 SMBMY

1
SembMarine acquiring IP rights of Sevan Marine for S$37m cash to resolve long-standing dispute

2018-06-08 theedgemarkets
SINGAPORE (June 8): Sembcorp Marine is acquiring the intellectual property rights of Norway’s Sevan Marine for US$28 million (S$37.4 million) in cash.
SMBMF S51 SMBMY

9
Transocean (RIG) Buys Stake in New Harsh Environment Rig

2018-05-10 zacks
Transocean Ltd. (RIG - Free Report) recently announced that the company has bought 33.3% interest in a newly built harsh environment semisubmersible, West Rigel. The semisubmersible was built by Sembcorp Marine Ltd.’s subsidiary, Jurong Shipyard Pte Ltd. and is worth $500 million.
SMBMF NINE OMP S51 RIG SMBMY CEO SGAZF

3
Transocean Acquires Interest in Harsh Environment Newbuild Semisubmersible

2018-05-09 globenewswire
STEINHAUSEN, Switzerland, May 09, 2018 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE:RIG) announced today that, through a joint venture with funds managed and/or advised by Hayfin Capital Management LLP (“Hayfin”), it has purchased a 33.3% interest in the West Rigel, a newbuild harsh environment semisubmersible. The total purchase price for the rig, built by Sembcorp Marine Ltd.’s (“Sembcorp”) Jurong Shipyard Pte Ltd, is $500 million.
SMBMF S51 RIG SMBMY SGAZF

2
Sembcorp Marine Q1 profit slumps 86% - Channel NewsAsia

2018-04-26 channelnewsasia
SINGAPORE: Singaporean rig builder Sembcorp Marine on Wednesday (Apr 25) posted an 86 per cent fall in first-quarter profit and signalled a subdued outlook for rig orders.
SMBMF S51 U96 SCRPF SMBMY SCRPY

2
Singapore's Sembcorp Marine 1Q Profit Slumps 86%, Outlook Subdued

2018-04-25 rigzone
SINGAPORE, April 25 (Reuters) - Singaporean rig builder Sembcorp Marine Ltd said on Wednesday first-quarter profit fell 86 percent, and signalled a subdued outlook for orders and business volumes.
SMBMF S51 U96 SCRPF SMBMY SCRPY

24
Transocean April Fleet Status A Must Read

2018-04-20 seekingalpha
The offshore drilling industry is not doing exceptionally fantastic even if oil prices are bullish. RIG Backlog is still weakening.
SMBMF RDS.B S51 RDS.A RYDBF RDSB RDSA RYDAF RIG SMBMY

2
SembCorp Industries - Turnaround Story, Catalyzed By Business Overhaul And Macro Factors

2018-04-10 seekingalpha
Despite weakening financial performance, the recovery in oil prices and a change in leadership catalyze a compelling turnaround story.
SMBMF S51 U96 SCRPF SMBMY SCRPY

1
Sembcorp Nets Karish, Tanin FPSO Engineering Contract

2018-03-28 rigzone
Sembcorp Marine Ltd announced Wednesday that its wholly-owned subsidiary, Sembcorp Marine Rigs & Floaters Pte. Ltd., has secured a contract from TechnipFMC to undertake the engineering, procurement and construction of hull and living quarters for a newbuild Floating Production, Storage and Offloading vessel (FPSO).
SMBMF S51 SMBMY

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...